Investor directory

RMI Partners

RMI Partners is a venture company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies. In Eastern Europe and Russia, RMI Partners is one of the largest investors in life sciences. The company makes global investments in a variety of therapeutic areas. RMI Partners is currently managing the venture fund RusnanoMedInvest (RMI, a subsidiary of JSC RUSNANO), which was created in 2012 to develop innovative projects in the field of medicine and pharmaceutics. RMI’s portfolio includes companies from Russia, USA, UK and Israel, specializing in the development and marketing of innovative pharmaceutical and medical technologies, many of which successfully completed an initial public offering (IPO) on NASDAQ, or were purchased by strategic buyers.

Focus

Scale StageRussiaRISCCentral and Eastern EuropeEuropeShow more
http://rmivc.com
https://crunchbase.com/organization/rmi-partners
https://facebook.com/rmivc
https://linkedin.com/company/rmi-partners
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=253256753

30 past transactions

Epic Sciences

Series C in 2014
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Novadigm Therapeutics

Series B in 2014
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.

ReVision Optics

Series E in 2013
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Tragara

Series B in 2013
Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

Miramar Labs

Series D in 2014
Miramar Labs develops medical devices for aesthetic indications that treat primary axillary (underarm) hyperhidrosis in adults. The miraDry System cannot be used to treat hyperhidrosis elsewhere on the body, including the hands and feet. It was founded in 2006 and is based in Sunnyvale, California.

Novadigm Therapeutics

Series B in 2013
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.

Tragara

Series B in 2014
Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

Transcend Medical

Venture Round in 2015
Transcend Medical, Inc., an ophthalmic device company, engages in the development of medical devices for the treatment of glaucoma. The company offers CyPass Micro-Stent, a micro-invasive tent that is inserted in the eye during routine cataract surgery; Vold Gonio Lens for use in micro-invasive glaucoma surgery. It also provides clinical trial services. Transcend Medical, Inc. was formerly known as iART Newco I, Inc. The company was founded in 2005 and is based in Menlo Park, California. As of March 23, 2016, Transcend Medical, Inc. operates as a subsidiary of Alcon Holdings, Inc.

Novadigm Therapeutics

Convertible Note in 2017
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.

Atea Pharmaceuticals

Series A in 2014
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

Epic Sciences

Series D in 2017
Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Ocunexus Therapeutics

Series B in 2012
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Celtaxsys

Series D in 2015
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

Syndax Pharmaceuticals

Series C in 2015
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Tragara

Series C in 2015
Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

Syndax Pharmaceuticals

Series B in 2013
Syndax Pharmaceuticals is a clinical-stage pharmaceutical company that focuses on an HDAC inhibitor for solid tumors and hematological tumors. It offers therapies to treat solid tumors and lung, breast, and hematological cancer. The company is developing axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor, in development for chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor. Syndax Pharmaceuticals pipeline includes and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr and NPM1 acute leukemias.

Clearside Biomedical

Funding Round in 2016
Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Binx Health

Series C in 2015
Binx Health Limited, an in vitro diagnostics company, develops and provides diagnostic instrument and disposable cartridge systems for decentralized laboratory, point-of–care, and other near-patient settings. It offers io System, a diagnostic platform that is designed to detect the presence of infectious diseases, such as chlamydia and MRSA; and Callisto, a system that provides a solution to meet a range of throughput requirements. The company provides solutions for sexually transmitted infections and hospital acquired infections. Binx Health Limited has a strategic partnership with Sherlock Biosciences. The company was founded in 2005 and is based in Trowbridge, United Kingdom.

Celtaxsys

Series E in 2018
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

Tragara

Convertible Note in 2015
Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

ALDEA Pharmaceuticals

Series B in 2014
ALDEA Pharmaceuticals is developing small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) family, to treat toxic aldehyde-related diseases. This proprietary technology represents new product opportunities to address novel targets across multiple therapeutic areas. For example, an ALDH activator compound enhances the detoxification of acetaldehyde in the alcohol metabolism pathway, to treat acute symptoms and to reduce long-term tissue damage and cancer risk. The company was founded in 2011 and headquartered in Redwood City, California.

Binx Health

Series D in 2017
Binx Health Limited, an in vitro diagnostics company, develops and provides diagnostic instrument and disposable cartridge systems for decentralized laboratory, point-of–care, and other near-patient settings. It offers io System, a diagnostic platform that is designed to detect the presence of infectious diseases, such as chlamydia and MRSA; and Callisto, a system that provides a solution to meet a range of throughput requirements. The company provides solutions for sexually transmitted infections and hospital acquired infections. Binx Health Limited has a strategic partnership with Sherlock Biosciences. The company was founded in 2005 and is based in Trowbridge, United Kingdom.

Celtaxsys

Private Placement in 2018
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

Evofem Biosciences

Series C in 2012
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

ReVision Optics

Series E in 2013
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.

Clearside Biomedical

Series B in 2014
Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Tobira Therapeutics

Debt Financing in 2014
Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associated infectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.

Transcend Medical

Series C in 2014
Transcend Medical, Inc., an ophthalmic device company, engages in the development of medical devices for the treatment of glaucoma. The company offers CyPass Micro-Stent, a micro-invasive tent that is inserted in the eye during routine cataract surgery; Vold Gonio Lens for use in micro-invasive glaucoma surgery. It also provides clinical trial services. Transcend Medical, Inc. was formerly known as iART Newco I, Inc. The company was founded in 2005 and is based in Menlo Park, California. As of March 23, 2016, Transcend Medical, Inc. operates as a subsidiary of Alcon Holdings, Inc.

Marinus Pharmaceuticals

Venture Round in 2012
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.